The University of Virginia seeks adults ages 18 and over with locally advanced or metastatic resistant or refractory solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A, or other mutation with mechanistic rationale.
The primary goals of this study are:
- To assess the safety and tolerability of RP-6306, a first in class membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitor with RP-3500, an ataxia telangiectasia-mutated - and rad3-related (ATR) inhibitor in people with advanced solid tumors
- To determine the maximum tolerated dose (MTD) of RP-6306 combined with RP-3500 and determine recommended doses and schedules
All eligible participants will receive both study drugs; RP-6306 and RP-3500. Participants will receive study treatment up to discontinuation. This trial will last for approximately 30 months, with a 28 day screening period, 24 month treatment period (treatment period may vary), a 30 day safety follow-up, and survival follow-up for up to 1 year.
This study involves blood sampling, tumor biopsies, and an electrocardiogram (ECG). The study drug will be taken by mouth and participants will be given instructions and a dosing diary for drug administration.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
$65 per study visit